TRIALS IN TREATING STIs, VACCINES AND LIPID LOWERING MEDICATIONS
Dr Pi Lip Seet,
Principal Investigator
Paratus Clinical, Brisbane &
Surgical Registrar
Brisbane, Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane | March 2026
Dr Pi Lip Seet graduated from the University of Queensland with a Bachelor of Medicine and Bachelor of Surgery, after completing a Bachelor of Biomedical Science at the University of Newcastle. He has undertaken broad hospital-based training across Queensland and the ACT, with clinical experience in Emergency Medicine, General and Orthopaedic Surgery, Plastic and Reconstructive Surgery, Intensive Care and Coronary Care.
Since joining Paratus Clinical Research in 2022, Dr Seet has served as both Principal Investigator and Sub-Investigator across Phase I–IV industry-sponsored clinical trials. His research experience spans vaccines, immunology, cardiovascular and endocrine disease, respiratory medicine, gastroenterology, pain management, sleep medicine and adult psychiatry. He has been involved in multiple vaccine development programs, including RSV, influenza, COVID-19, herpes zoster and pneumococcal studies.
Dr Seet maintains current Good Clinical Practice certification and advanced life support training. With a strong foundation in acute and procedural medicine, he is committed to delivering high-quality, ethical clinical research, ensuring participant safety while supporting the advancement of innovative therapeutic and vaccine programs.
Source: Supplied
-
Engineering bacteria to detect colorectal cancer cells
An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
-
Health and economic burden of interstitial lung diseases
Dr Cox’s main research interests focus on respiratory diseases and primarily on the economic burden and economic evaluation of interventions and treatments for their management. She earned her PhD from the University of Tasmania where her doctoral research examined the health and economic burden of idiopathic pulmonary fibrosis (IPF) in Australia, one component of the NHMRC Centre for Research Excellence for Pulmonary Fibrosis, a national project implemented alongside the Australian IPF Registry and the Lung Foundation Australia. This research provided the first epidemiological profile and first costing estimates of the economic burden of the disease in Australia, providing essential evidence for health service reimbursement policies.
-
Next Generation Condom Contraception, Dr David Shepherd
Dr David Shepherd is a Lead Production Engineer and Materials Specialist at Eudaemon Technologies. His journey began at the University of Wollongong, where he pursued advanced studies and eventually obtained a PhD under the guidance of a distinguished professor. His research initially focused on actuating materials and artificial muscles, particularly centred around hydrogel materials. These early explorations have seamlessly evolved into his current focus on utilising hydrogels in the realm of sexual reproductive health, with a specific emphasis on developing innovative hydrogel condoms.
